ENSC Ensysce Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1716947 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY37.9%
TTM net income YoY-729.4%
TTM EPS YoY-18.3%
Revenue 3-yr CAGR25.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,477.0%
Net margin-1,470.4%
FCF margin—
EBITDA margin-1,476.6%
Returns
ROE-635.4%
ROA-533.3%
ROIC (approx.)—
Asset turnover0.36x
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.02x
Interest coverage-7,157.58x
Cash quality & payout
Operating cash flow / net income0.09x
Accruals ratio-484.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.07M | $5.21M | $2.23M | $2.52M | $3.53M |
| R&D expense | $10.38M | $7.22M | $7.59M | $19.84M | $4.69M |
| SG&A expense | $4.93M | $4.72M | $5.36M | $6.91M | $18.71M |
| Operating income | -$10.24M | -$6.73M | -$10.72M | -$24.22M | -$19.87M |
| Interest expense | $18,767 | $1.29M | $353,945 | $109,525 | $1.30M |
| Net income | -$10.18M | -$7.99M | -$10.61M | -$24.17M | -$29.08M |
| EBITDA | -$10.23M | -$6.73M | -$10.72M | -$24.22M | -$19.87M |
| EPS (basic) | -3.98 | -11.45 | -70.40 | -139.42 | -29.64 |
| EPS (diluted) | -3.98 | -11.45 | -70.40 | -139.42 | -1.48 |
| Weighted avg. shares (diluted) | 2.56M | 697,686 | 150,937 | 179,925 | 20.16M |
| Banking | |||||
| Provision for credit losses | — | — | -$150 | -$3 | -$1,808 |
| Balance sheet | |||||
| Cash & equivalents | $4.31M | $3.50M | $1.12M | $3.15M | $12.26M |
| Current assets | $7.25M | $5.34M | $2.29M | $5.30M | $15.66M |
| PP&E, net | $124,129 | — | — | — | — |
| Total assets | $7.45M | $5.60M | $2.71M | $5.89M | $16.42M |
| Current liabilities | $4.57M | $2.21M | $3.33M | $9.46M | $16.48M |
| Total liabilities | $4.57M | $2.22M | $3.36M | $9.91M | $24.58M |
| Shareholders' equity | $3.21M | $3.71M | -$322,858 | -$3.71M | -$7.88M |
| Shares outstanding | 4.57M | 1.36M | 209,739 | 534,490 | 1.23M |
| Cash flow statement | |||||
| Operating cash flow | -$7.81M | -$7.50M | -$10.78M | -$17.89M | -$8.24M |
| Capital expenditure | $123,643 | — | — | — | — |
| Free cash flow | -$7.93M | — | — | — | — |
| Investing cash flow | -$123,643 | — | — | $4,500 | — |
| Financing cash flow | $8.74M | $9.88M | $8.76M | $8.77M | $20.31M |
| Depreciation & amortization | $6,533 | $0 | $0 | $0 | $151 |
| Stock-based compensation | $177,086 | $110,723 | $879,160 | $1.07M | $121,764 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.